FDA 510(k)

TRI-POINT LIQUIMMUNE IMMUONASSAY CONTROL, L-1,2,3

K-Number: K931366 · 1993-07-28

Decision Date1993-07-28

Product CodeJJY

Advisory CommitteeCH

DecisionSubstantially Equivalent

Device Summary

TRI-POINT LIQUIMMUNE IMMUONASSAY CONTROL, L-1,2,3 is the device name listed in this FDA 510(k) record. The listed applicant is Medical Analysis Systems, Inc.. It received FDA 510(k) clearance on 1993-07-28 under 510(k) number K931366. The device is classified under product code JJY. It was reviewed by the CH advisory panel. FDA Decision: Substantially Equivalent.

Frequently Asked Questions

What is the TRI-POINT LIQUIMMUNE IMMUONASSAY CONTROL, L-1,2,3?

TRI-POINT LIQUIMMUNE IMMUONASSAY CONTROL, L-1,2,3 is a medical device that received FDA 510(k) clearance on 1993-07-28. The listed applicant is Medical Analysis Systems, Inc.. The 510(k) number is K931366.

When did TRI-POINT LIQUIMMUNE IMMUONASSAY CONTROL, L-1,2,3 receive FDA 510(k) clearance?

TRI-POINT LIQUIMMUNE IMMUONASSAY CONTROL, L-1,2,3 received FDA 510(k) clearance on 1993-07-28, under 510(k) number K931366.

Who is the listed applicant for TRI-POINT LIQUIMMUNE IMMUONASSAY CONTROL, L-1,2,3?

The FDA 510(k) record lists Medical Analysis Systems, Inc. as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for TRI-POINT LIQUIMMUNE IMMUONASSAY CONTROL, L-1,2,3?

The FDA product code for TRI-POINT LIQUIMMUNE IMMUONASSAY CONTROL, L-1,2,3 is JJY.

Related Clinical Trials

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

NCT07608549FLASH Pilot Phase 1 Safety StudyNOT_YET_RECRUITING NCT06562205PAP Systems External Clinical Studies (ECS)NOT_YET_RECRUITING NCT06443177The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid HemorrhageSUSPENDED NCT07095751Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder CancerNOT_YET_RECRUITING

Other records listing Medical Analysis Systems, Inc. as applicant

K042717MAS, DADE AND LIQUID ASSAYED DIABETES CONTROL K041194ABBOTT ARCHITECT STAT TROPONIN I LIQUID ASSAYED CARDIAC MARKER CONTROL LEVEL L, M AND H K040880MAS CARDIOIMMUNE TL LIQUID ASSAYED CARDIAC MARKER CONTROL, LEVELS 1,2 AND 3 K032826MAS PAR TDM K032335MAS CARDIOIMMUNE PROBNP, MAS CARDIOIMMUNE TL K031890MAS BILIRUBIN LIQUID ASSAYED BILIRUBIN CONTROL

View all 107 devices →

Related Devices (Code: JJY)

K162530Multichem IA PlusTechno-Path Manufacturing K163629Audit MicroControls Linearity FD Tumor Markers IIAalto Scientific, Ltd.K163015Liquichek Tumor Marker Control-Level 1; Liquichek Tumor Marker Control-Level 2; Liquichek Tumor Marker Control-Level 3; Liquichek Tumor Marker Control- Trilevel MiniPakBio-Rad Laboratories K153712VK-3 Verification Kit, VK-4 Verification Kit, VK-R5 Verification Kit, VK-R7 Verification Kit, VK-Crea Verification KitRadiometer America, Inc.K132227LIQUICHEK IMMUNOASSAY PREMIUM CONTROL-TRILEVEL, LIQUICHEK IMMUNOASSAY PREMIUM CONTROL-LEVEL I, LIQUICHEK IMMUNOASSAYBio-Rad Laboratories K132156RANDOX CSF CONTROLS LEVELS 2 AND 3Randox Laboratories, Ltd.

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.